NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report released on Friday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO opened at $4.44 on Friday. The stock’s 50 day simple moving average is $3.89 and its 200 day simple moving average is $3.78. NeuroMetrix has a 1 year low of $2.70 and a 1 year high of $11.55.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Thursday, February 22nd. The medical device company reported ($1.43) earnings per share (EPS) for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%. The company had revenue of $1.32 million for the quarter.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC acquired a new position in NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned about 2.80% of NeuroMetrix as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.